Positive Results from the Scandion Oncology A/S and Alligator Bioscience AB Collaboration Further Supports Efficacy of SCO-101 in Combination Therapy

Copenhagen, Denmark, September 2, 2021 – Scandion Oncology (Nasdaq Stockholm: SCOL) and Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced the conclusion of their collaboration with a very positive outcome.

The release as fetched from its publisher. scandiononcology.com ↗